Sónia Gonçalves

Dr. Sónia Gonçalves

Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal
orcid

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 February 2017 in Frontiers in Chemistry
Verified
Journal Article
Open access
MFMário Felício
Mário Felício
OSOsmar N. Silva
Osmar N. Silva
SGSónia Gonçalves
Sónia Gonçalves
Nuno SantosNuno Santos
Nuno Santos
Octavio FrancoOctavio Franco
Octavio Franco
In recent years, the number of people suffering from cancer and multi-resistant infections has increased, such that both diseases are already seen as current and future major causes of death. Moreover, chronic infections are one of the main causes of cancer, due to the instability in the immune system that allows cancer cells to proliferate. Likewise, the physical debility associated with cancer or with anticancer therapy itself often paves the way for opportunistic infections. It is urgent to develop new therapeutic methods, with higher efficiency and lower side effects. Antimicrobial peptides (AMPs) are found in the innate immune system of a wide range of organisms. Identified as the most promising alternative to conventional molecules used nowadays against infections, some of them have been shown to have dual activity, both as antimicrobial and anticancer peptides (ACPs). Highly cationic and amphipathic, they have demonstrated efficacy against both conditions, with the number of nature-driven or synthetically designed peptides increasing year by year. With similar properties, AMPs that can also act as ACPs are viewed as future chemotherapeutic drugs, with the advantage of low propensity to resistance, which started this paradigm in the pharmaceutical market. These peptides have already been described as molecules presenting killing mechanisms at the membrane level, but also acting towards intracellular targets, which increases their success comparatively to specific one-target drugs. This review will approach the desirable characteristics of small peptides that demonstrated dual activity against microbial infections and cancer, as well as the peptides engaged in clinical trials.

25 June 2018 in Frontiers in Chemistry
Verified
Journal Article
Open access
PDF file
Patricia CarvalhoPatricia Carvalho
Patricia Carvalho
MFMário Felício
Mário Felício
Nuno SantosNuno Santos
Nuno Santos
SGSónia Gonçalves
Sónia Gonçalves
MDMarco Domingues
Marco Domingues
Over the years, the scientific importance of nanoparticles for biomedical applications has increased. The high stability and biocompatibility, together with the low toxicity of the nanoparticles developed lead to their use as targeted drug delivery systems, bioimaging systems, and biosensors. The wide range of nanoparticles size, from 10 nm to 1 μm, as well as their optical properties, allow them to be studied using microscopy and spectroscopy techniques. In order to be effectively used, the physicochemical properties of nanoparticle formulations need to be taken into account, namely, particle size, surface charge distribution, surface derivatization and/or loading capacity, and related interactions. These properties need to be optimized considering the final nanoparticle intended biodistribution and target. In this review, we cover light scattering based techniques, namely dynamic light scattering and zeta-potential, used for the physicochemical characterization of nanoparticles. Dynamic light scattering is used to measure nanoparticles size, but also to evaluate their stability over time in suspension, at different pH and temperature conditions. Zeta-potential is used to characterize nanoparticles surface charge, obtaining information about their stability and surface interaction with other molecules. In this review, we focus on nanoparticle characterization and application in infection, cancer and cardiovascular diseases.

1 September 2004 in Fuel
Verified
Journal Article
Closed access
SGSónia Gonçalves
Sónia Gonçalves
JCJ Castillo
J Castillo
AFA Fernández
A Fernández
JHJ Hung
J Hung

1 March 2018 in Biotechnology Advances
Verified
Journal Article
Closed access
BGBárbara Gomes
Bárbara Gomes
MAMarcelo T. Augusto
Marcelo T. Augusto
MFMário Felício
Mário Felício
AHAxel Hollmann
Axel Hollmann
Octavio FrancoOctavio Franco
Octavio Franco
Nuno SantosNuno Santos
Nuno Santos

8 November 2019 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
MMMarcin Makowski
Marcin Makowski
ISItala Silva
Itala Silva
CAConstança Pais do Amaral
Constança Pais do Amaral
SGSónia Gonçalves
Sónia Gonçalves
Nuno SantosNuno Santos
Nuno Santos
Antimicrobial peptides (AMPs) have been described as excellent candidates to overcome antibiotic resistance. Frequently, AMPs exhibit a wide therapeutic window, with low cytotoxicity and broad-spectrum antimicrobial activity against a variety of pathogens. In addition, some AMPs are also able to modulate the immune response, decreasing potential harmful effects such as sepsis. Despite these benefits, only a few formulations have successfully reached clinics. A common flaw in the druggability of AMPs is their poor pharmacokinetics, common to several peptide drugs, as they may be degraded by a myriad of proteases inside the organism. The combination of AMPs with carrier nanoparticles to improve delivery may enhance their half-life, decreasing the dosage and thus, reducing production costs and eventual toxicity. Here, we present the most recent advances in lipid and metal nanodevices for AMP delivery, with a special focus on metal nanoparticles and liposome formulations.

1 April 2016 in Pharmacology & Therapeutics
Verified
Journal Article
Closed access
SRSuzana Ribeiro
Suzana Ribeiro
MFMário Felício
Mário Felício
EBEsther Vilas Boas
Esther Vilas Boas
SGSónia Gonçalves
Sónia Gonçalves
FCFabrício F. Costa
Fabrício F. Costa
Octavio FrancoOctavio Franco
Octavio Franco